Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines

Fumito Ito,1,2 Qiao Li,1 Andrew B. Shreiner,1 Ryuji Okeyama,1 Maria N. Jure-Kunkel,3 Seagal Teitz-Tennenbaum,1 and Alfred E. Chang1

1Division of Surgical Oncology, University of Michigan Medical Center, Ann Arbor, Michigan; 2Department of Surgery, Shiga University of Medical Science, Shiga, Japan; and 3Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey

INTRODUCTION

The use of dendritic cells (DCs) as vaccine reagents has become an area of intense focus in the field of cancer immunotherapy. DCs can be pulsed with tumor-associated antigen by a variety of methods that result in the ability of DCs to prime naïve T cells, and DCs can mediate regression of established tumor when given as a vaccine in animal models (1–5). Despite these promising preclinical observations, the initial clinical studies evaluating DC-based vaccines have demonstrated limited success (6–10). Several of these studies have found that immune responses to tumor antigen as measured by in vitro cytokine release of VPLNs and spleen cells in response to tumor antigen toward a type 1 (interferon-γ) versus a type 2 (interleukin-4) profile. Cell depletion and the use of anti-CD137 monoclonal antibody after tumor lysate-pulsed dendritic cell (TP-DC) vaccination. TP-DC subcutaneous vaccination induced a transient up-regulation of CD137 on T cells and natural killer (NK) cells within vaccine-primed lymph nodes (VPLNs). In established pulmonary and subcutaneous tumor models, anti-CD137 synergistically enhanced tumor regression after TP-DC vaccination. In the subcutaneous tumor model, the combined therapy resulted in improved survival. Combined therapy also resulted in improved local control of subcutaneous tumor after surgical resection. Anti-CD137 polarized the cytokine release of VPLNs and spleen cells in response to tumor antigen toward a type 1 (interferon-γ) versus a type 2 (interleukin-4) profile. Cell depletion and the use of anti-CD137 monoclonal antibody (mAb) to CD137. Melero et al. (15) were the first to report that anti-CD137 mAb (anti-4-1BBmAb) can be administered in vivo to mediate antitumor responses against established weakly immunogenic tumors in animal models. Against poorly immunogenic or nonimmunogenic tumors, it was reported by the same group that tumor regression required active immunization with a peptide vaccine + anti-CD137 (16). It was apparent from these and other studies that anti-CD137 administration can provide potent in vivo costimulation of cellular immune responses and may be a useful reagent to examine with DC-based vaccines.

In this report, we examined the role of anti-CD137 administration in modulating the immune responses induced by tumor lysate-pulsed DC (TP-DC) vaccinations. Tumor lysates provide the ability to sensitize T cells to the entire spectrum of tumor-associated antigens specific for an individual tumor. This has formed the rationale for clinical trials we and others have conducted (6, 10). The studies in this report involve the treatment of both weakly and poorly immunogenic established tumors. We describe herein the effects of anti-CD137 on the immune function of vaccine-primed T cells and how NK cells modulate this function.

MATERIALS AND METHODS

Mice. Female C57BL/6 (B6) mice, 6–8 weeks of age, were purchased from Harlan Laboratories (Indianapolis, IN). Female B6 129-J1Il15rant1/Ama, B6 129S2-Cd4tm1Mak, and B6 129S2-Cd8tm1Mak knockout (KO) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Hemizygous OT-1 T-cell receptor transgenic mice maintained on a C57BL/6-Cd45.1 background were a generous gift from Dr. Kevin McDonagh (University of Michigan, Ann Arbor, MI). All mice were maintained in specific pathogen-free conditions and used at 10 to 14 weeks of age. The University of Michigan Laboratory of Animal Medicine approved all animal protocols.

Tumors. MCA 205 and MCA 207 murine tumors are 3-methylcholanthrene–induced fibrosarcomas, syngeneic to B6 mice. These tumors have been characterized previously as weakly immunogenic with distinct tumor-specific transplantation/rejection antigens (17). These tumors have been maintained in vivo by serial subcutaneous transplantation in B6 mice and were used within the 8th passage. Tumor cell suspensions were prepared from solid tumors by enzymatic digestion in 40 mL of Hanks’ balanced salt solution (Life Technologies, Inc., Grand Island, NY) containing 40 mg of collagenase, 4 mg of DNase I, and 100 units of hyaluronidase (all enzymes were from Sigma, St. Louis, MO) for 2 to 3 hours at room temperature, as described previously (18). Tumor cells were washed three times in Hanks’ balanced salt solution for administration to mice or resuspended in complete medium (CM) for in vitro assays. CM consisted of RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 mg/mL streptomycin, 100 units/mL penicillin, 50 µg/mL gentamicin, 0.5 µg/mL Fungizone (all from Life Technologies, Inc.), and 0.05 mM L-mercaptoethanol (Sigma).

The B16-BL6 melanoma is a poorly immunogenic melanoma of spontaneous origin (19). B16-OVA is a tumor line transfected to express ovalbumin (OVA) that serves as a tumor-associated antigen. This line was obtained from Dr. Kenneth Rock (University of Massachusetts, Amherst, MA). EL-4 is a T-cell thymoma syngeneic to B6 mice. RMAS cells are TAP-deficient cells that are defective in transporters associated with antigen processing and
express functionally “empty” class I major histocompatibility complex molecules on the cell surface (20).

**Antibody and Cytokines.** Agonistic anti-CD137 mAb (1D8) was kindly provided by Bristol-Myers Squibb Co., Pharmaceutical Research Institute (Princeton, NJ). ID8 is a rat IgG2a class of antibody. Recombinant murine granulocyte macrophage colony-stimulating factor and recombinant murine interleukin (IL)-4 were purchased from PeproTech (Rocky Hill, NJ).

**Generation of Bone Marrow-derived Dendritic Cells and Tumor Lysate Pulsing.** Erythrocyte-depleted bone marrow cells were cultured in CM supplemented with 10 ng/mL granulocyte macrophage colony-stimulating factor and 10 ng/mL IL-4 at 1 × 10^7 cells per mL. On day 5, nonadherent cells were harvested by gentle pipetting. DCs were enriched by density centrifugation over 14.5% (w/v) metrizamide (Sigma), and the low-density interface was collected. DCs were washed twice, enumerated, and used for in vitro and in vivo functional studies. For preparation of tumor lysate, MCA 205, B16-BL6, B16-OVA, and EL-4 cells were suspended in PBS and subjected four times to rapid freeze-thaw exposures and then spun at 100,000 × g for 5 minutes to remove cellular debris. The DCs were resuspended at 1 × 10^6 cells per mL in CM and incubated with tumor lysate at a tumor cell equivalent to DC ratio of 3:1 for 18 hours.

**OT-1 Cell Purification and Labeling.** Freshly isolated splenocytes and popliteal, inguinal, mesenteric, axillary, and brachial lymph node (LN) cells from OT-1 transgenic mice (Ly5.1) were prepared as single cell suspensions and pooled. Lymphoid cells were enriched by the Magnetic Activated Cell Sorting device (Miltenyi Biotec, Auburn, CA), using the CD8a^+ T-cell isolation kit according to the manufacturer’s protocol (Miltenyi Biotec). The fraction of tetramer-positive CD8^+ T cells averaged between 93% and 97% of the total population by flow cytometry. Cells were suspended at 10^7 cells per mL in PBS and incubated with 5- and 6-carboxyfluorescein diacetate succinimidyl ester (CFSE; C-1157; Molecular Probes, Inc., Eugene, OR) at concentrations of 1 μmol/L for 10 minutes at room temperature in the dark and washed twice with PBS. Based on flow cytometry, a total lymphoid cell suspension containing 4 to 5 × 10^6 tetramer-positive CD8^+ T cells was injected intravenously into C57BL/6 (Ly5.2) mice. To assess proliferation and CD62L expression of OT-1 cells in vaccine-primed lymph nodes (VPLNs), 0.5 to 1.0 × 10^6 events were collected and analyzed by flow cytometry.

**Flow Cytometry.** The following antibodies were used in this study: purified rat anti-CD16/32 (2.4G2), fluorescein isothiocyanate (FITC)-labeled anti-CD3ε (145-2C11), phycoerythrin (PE)-labeled anti-NK1.1 (PK136), FITC- and PE-labeled anti-CD4 (GK1.5; rat IgG2b), CyChrome anti-CD8a (53-6.7), PE-labeled anti-CD62L (Mel-14), PE- and biotin-labeled anti-CD45.1 (Ly5.1; A20), streptavidin CyChrome conjugate (all from BD PharMingen, San Diego, CA), and FITC-labeled anti-CD8a (5H10; rat IgG2b; Caltag, Burlingame, CA).

Before staining, cells were incubated with 2.4G2 mAb on ice for 15 minutes to prevent nonspecific binding of mAbs. All procedures were performed using cold PBS containing 5% fetal bovine serum. VPLN cell surface expression of CD137 was assessed by indirect immunofluorescence assays using purified anti-CD137 mAbs (1D8; rat IgG2a) followed by biotin-labeled antirat IgG2a (RG7/1.30), and purified rat IgG2a isotype standard (R35-95) was used as a control (both from BD PharMingen). To assess CD137 expression on NK cells
and CD4\(^+\) and CD8\(^+\) T cells in VPLNs, 3 \(\times\) 10\(^5\), 0.5 \(\times\) 10\(^6\), and 0.5 \(\times\) 10\(^6\) events were collected in a FACSscan flow cytometer, respectively. FACS-Calibur with CellQuest software was obtained from Becton Dickinson (San Diego, CA).

**Assessment of Cytokine Release in Response to Tumor Cells.** To measure cytokines released by VPLNs and spleen cells in response to tumor stimulation, 1.0 \(\times\) 10\(^6\) lymphoid cells were cocultured with 0.1 \(\times\) 10\(^6\) irradiated (6,000 rads) MCA 205 tumor cells or irradiated (10,000 rads) RMAS cells. RMAS cells were loaded with OVA-peptide, and SIINFEKL) at 10 \(\mu\)mol/L in 2-mL volumes per well in 24-well culture plates for 24 hours at 37°C. The culture supernatants were then collected and analyzed for cytokine production using ELISAs. Irradiated MCA 207 and RMAS cells without peptide were used as specificity controls.

**Treatment of Established Pulmonary Metastases.** B6 mice received 2 \(\times\) 10\(^5\) MCA 205 or 1 \(\times\) 10\(^4\) B16-BL6 viable tumor cells intravenously on day 0. The mice were then immunized intradermally with 1.5 to 2.0 \(\times\) 10\(^6\) MCA 205, B16-BL6, or EL-4 TP-DCs on day 3 (treatment of 3-day–old lung metastases) or on days 10 and 14 (treatment of 10-day–old lung metastases). Anti-CD137 mAb (1D8) or control rat IgG (Sigma) was given intraperitoneally (100 \(\mu\)g) in 0.5 mL of PBS on days 4 and 7 (treatment of 3-day–old lung metastases) or on days 11, 14, and 17 (treatment of 10-day–old lung metastases). Mice were sacrificed on day 15 (for 3-day–old lung metastases) or 20 (for 10-day–old lung metastases) to enumerate lung metastases. Five mice were used in each experimental group. Intratracheal instillation with India ink was performed to stain the lung parenchyma (21). The MCA 205 metastases appeared as discrete white nodules on the black surface of lungs. For enumeration of B16-BL6 tumors, Fekete’s solution was instilled in the lungs via the trachea.

**Treatment of Established Subcutaneous Tumor.** B6 mice were inoculated subcutaneously in the mid-right flank with 2 \(\times\) 10\(^5\) MCA 205 viable tumor cells on day 0. The mice were then immunized intradermally with 1.5 to 2.0 \(\times\) 10\(^6\) MCA 205 TP-DCs on days 7 and 11. Anti-CD137 mAb (1D8) or control rat IgG was given intraperitoneally (100 \(\mu\)g) in 0.5 mL of PBS on days 8, 11, and 14. The largest perpendicular diameters of tumors were measured in a blinded coded fashion using vernier calipers, and size was recorded as tumor area (in mm\(^2\)). Data are reported as the average tumor area \(\pm\) SEM of six or more mice per group.

**In vivo Cell Depletion.** Anti-NK1.1 hybridoma cells were used to produce the PK136 mouse IgG2a mAb (HB191; American Type Culture Collection, Manassas, VA). Hybridoma cells were inoculated into pristine-primed immunocompromised DBA/2 mice as described previously to generate ascites (22). MAb was purified from ascites fluid by ImmunoPure Immobilized Protein A/G gel (Pierce, Rockford, IL). The optimal amount of purified PK136 mAb for in vivo depletion was 400 \(\mu\)g intraperitoneally and was determined in preliminary functional assays of NK activity and flow cytometry (data not shown). The anti-CD4\(^+\) mAb (GK1.5) and the anti-CD8\(^+\) mAb (2.43; rat IgG2a) were purchased from Bozelogy (Broomfield, CO.). The optimal amount of mAbs for in vivo depletion of CD4\(^+\) or CD8\(^+\) cells was determined in preliminary assays and found to be 800 and 400 \(\mu\)g intraperitoneally, respectively.

**Statistical Analysis.** For comparison of treatment groups, a one-way analysis of variance (followed by a Newman-Keuls post hoc test) was performed using tumor measurements taken on the last day recorded for comparison of treatment groups. Student’s t test was used to analyze cell proliferation and cytokine release data. All statistical analysis was performed using GraphPad Prism software (San Diego, CA). Statistical significance was achieved when \(P\) was <0.05.

**RESULTS**

**TP-DC Vaccination Modulates CD137 Expression.** CD137 expression was assessed before and after DC vaccination in the VPLNs and spleen. As shown in Fig. 1A, CD137 expression on CD3\(^+\) VPLN cells was negligible before vaccination. TP-DC vaccination resulted in 3.1% of CD3\(^+\) cells in the VPLNs expressing CD137 on day 3 compared with <1% of CD3\(^+\) cells in VPLN cells from animals inoculated subcutaneously with PBS or unpulsed DCs (UP-DCs). In the same experiment, CD3\(^+\) splenocytes from vaccinated mice did not have significantly altered CD137 expression at 3 or 7 days after vaccination (Fig. 1B).

Analysis of different lymphoid subsets (NK, CD4\(^+\), and CD8\(^+\)) for CD137 expression was performed after TP-DC vaccination. Three days after TP-DC vaccination, the percentage of NK, CD4\(^+\), and CD8\(^+\) cells was 1.4%, 16.1%, and 57.1%, respectively (Fig. 2A). The expression of CD137 in these subpopulations is depicted in Fig. 2B. There was up-regulation of CD137 after TP-DC vaccination in all subpopulations compared with PBS-treated control mice. This was most notable in the CD3\(^+\) NK1.1\(^+\) cells population. No CD137 up-regulation was observed on CD3\(^+\) NK1.1\(^+\) cells (data not shown).

**Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines.** We evaluated the antitumor activity of anti-CD137 administration in a 3-day pulmonary metastasis model. The first tumor evaluated was MCA 205 sarcoma, a weakly immunogenic tumor. As shown in Fig. 3A, mice treated with anti-CD137 alone or TP-DC vaccine had significantly reduced numbers of lung metastases compared with control animals. However, the combination of anti-CD137 + TP-DCs resulted in the greatest reduction of metastatic tumor, indicating an additive effect of the combined treatment. Using the nonimmunogenic B16-BL6 melanoma, we found that the combination therapy using anti-CD137 and TP-DCs was synergistic in mediating the regression of 3-day–old lung tumors (Fig. 3B). There was no antitumor effect with anti-CD137 alone or in combination with UP-DCs or EL-4 lysate-pulsed DCs. The latter represented a specificity control for B16-BL6. However, the combined therapy using anti-CD137 + B16-BL6 lysate-pulsed DCs resulted in significant tumor regression compared with all other groups.
We next looked at the treatment of advanced (10-day–old) MCA 205 pulmonary metastases. As shown in Fig. 4, immunotherapy using anti-CD137 alone or in combination with UP-DCs had no antitumor activity against 10-day–old metastases. Similarly, UP-DCs or TP-DCs alone showed no therapeutic activity. However, the combination of TP-DC vaccination + anti-CD137 administration resulted in significant tumor regression. This demonstrated a synergism between anti-CD137 and TP-DCs in generating an immune response within the host to reject advanced tumor burdens.

In the lung tumor models, we examined the effect of titrating the dose on anti-CD137 and maximizing therapy. In Fig. 5A, mice with 3-day–old lung metastases were treated intraperitoneally with either 50, 100, or 200 μg of anti-CD137 on days 1 and 4 after TP-DC immunization on day 0. Control group received either PBS + rat IgG (200 μg), PBS + anti-CD137 (200 μg), or TP-DC + rat IgG (200 μg). *, P < 0.001 versus all other groups. In Fig. 5B, continued treatment with TP-DC + anti-CD137 augmented antitumor efficacy. Mice with 10-day–old pulmonary metastases were treated with either TP-DC immunization × 1 (day 10) and anti-CD137 administration × 2 (day 11 and 14), TP-DC immunization × 2 (day 10 and 14) and anti-CD137 administration × 3 (day 11, 14, and 17), or TP-DC immunization × 3 (day 10, 14, and 17) and anti-CD137 administration × 4 (day 11, 14, 17, and 18). **, P < 0.001 versus all other groups.

Using the subcutaneous tumor model, we examined the impact of combined TP-DC therapy + anti-CD137 on survival. Mice were inoculated with MCA 205 subcutaneously and treated with different combinations of therapy as described in Materials and Methods. Therapy with anti-CD137 + PBS or TP-DCs + rat IgG had no effect on the growth of subcutaneous tumors compared with control animals (Fig. 6A). However, the combined treatment of TP-DCs + anti-CD137 resulted in a significant reduction of tumor growth. This translated to significantly improved survival, as shown in Fig. 6B.

We went on to examine the effect of TP-DCs + anti-CD137 on minimal residual disease after surgical resection. B16-BL6 melanoma
cells were inoculated subcutaneously in the flanks of mice. On day 10, the tumors were resected, and mice received two TP-DC vaccinations and anti-CD137 as described in Fig. 7. Local tumor recurrence was the primary endpoint. By day 40, the group treated with TP-DCs + anti-CD137 had the lowest recurrence rate compared with the groups receiving monotherapy or control treatment (Fig. 7A). This group also had the best survival rate compared with the other groups (Fig. 7B).

Polarization Effect of Anti-CD137 during TP-DC Vaccination in Shifting Tumor-reactive T Cells Toward a Type 1 Phenotype.

To investigate the mechanisms involved in the augmented therapeutic efficacy demonstrated by TP-DC + anti-CD137 administration, we examined the immune function of T cells from VPLNs and spleens of treated mice. Mice with 3-day-old MCA 205 pulmonary metastases were inoculated with TP-DC and anti-CD137 as described in Fig. 8. VPLNs and spleens were harvested on day 9 for immune function analysis. Anti-CD137 administration alone resulted in no differences in interferon (IFN)-γ or IL-4 released by VPLNs or splenocytes compared with control animals. TP-DC administration alone resulted in the production of a modest amount of IFN-γ and IL-4 by both VPLNs and splenocytes in response to MCA 205 tumor cells. There was a significant increase in the amount of IFN-γ released by these cell populations from mice that received both TP-DCs and anti-CD137 (Fig. 8A). This response was immunologically specific. By contrast, the administration of anti-CD137 in conjunction with TP-DCs resulted in significantly decreased IL-4 release (Fig. 8B).

TP-DC and Anti-CD137 Combined Treatment Enhances the Generation of Both CD4⁺ CD62Llow and CD8⁺ CD62Llow Cells.

To further characterize the host lymphoid response to TP-DC + anti-CD137 therapy, we evaluated the expression of CD62L (selectin) on CD4⁺ and CD8⁺ VPLN cells. Mice were treated identically to the protocol described above, and VPLN cells were harvested 9 days after intravenous tumor infusion. Using three-color staining, CD4⁺ and CD8⁺ VPLN cells were gated to evaluate CD62L expression. TP-DC administration without anti-CD137 increased the percentage of CD62Llow-expressing CD4⁺ cells from 17% to 27%. The addition of anti-CD137 further increased the percentage of CD62Llow-expressing CD4⁺ cells to approximately 34%. A similar but more pronounced effect in increasing the number of CD62Llow-expressing cells was observed with the CD8⁺ T-cell subset. TP-DC vaccination without anti-CD137 increased the percentage of CD62Llow-expressing CD8⁺ cells from 10% to 26%. The addition of anti-CD137 further increased the percentage of CD62Llow-expressing CD8⁺ cells to 52%. We consider this a significant observation because it has previously been reported that effector T cells capable of mediating tumor rejection in vivo are concentrated in the CD62Llow-expressing cell populations (23, 24).

Fig. 6. Anti-CD137 mAb administration augmented antitumor reactivity of TP-DC immunization in established 7-day subcutaneous tumor and prolonged survival. B6 mice were inoculated subcutaneously with 2 × 10⁵ MCA 205 tumor cells on day 0. Mice bearing 7-day tumors were treated either with PBS or TP-DC immunization on day 7 followed by either rat IgG or anti-CD137 administration on days 8 and 11. A. Data are reported as the average tumor area ± SE of six mice per group. *, *P < 0.001 for TP-DC + anti-CD137 versus all other groups. B. Survival was monitored over time after tumor inoculation, and the median survival time (MST, in days) was determined. *, *P < 0.0001 for TP-DC + anti-CD137 versus all other groups.

Fig. 7. Combined therapy with TP-DC + anti-CD137 mAb resulted in lower local recurrence rates and improved survival after surgical resection of subcutaneous tumors. B6 mice were inoculated subcutaneously with 1 × 10⁶ B16-BL6 tumor cells in the flank. Ten days later, the tumors were surgically excised. TP-DCs (10⁷) were administered on days 13 and 17 along with anti-CD137 (100 μg) on days 14 and 17. Control groups received PBS + rat IgG, TP-DC + rat IgG, or PBS + anti-CD137. Each group consisted of 10 mice. A, percentage of local recurrence. *, *P < 0.004 versus PBS + rat IgG and PBS + anti-CD137. B, survival of animals. *, *P < 0.004 versus PBS + rat IgG and PBS + anti-CD137.
Identification of the Effector Cells Mediating Tumor Regression In vivo. We sought to identify the effector cells involved in the tumor rejection response associated with TP-DC + anti-CD137 therapy by using mAbs to deplete NK, CD4⁺, and CD8⁺ cells or by using KO mice. In antibody depletion experiments, the antitumor efficacy of TP-DC + anti-CD137 combined therapy was completely abrogated by the depletion of CD8⁺ T cells (Fig. 9A). Partial abrogation was observed by the depletion of CD4⁺ or NK cells. Use of KO mice devoid of NK, CD4⁺, or CD8⁺ cells confirmed this observation (Fig. 9B). The antitumor activity was completely abrogated in CD8 KO hosts and IL-15 KO hosts and partially abrogated in the CD4 KO mice. We concluded that the complete abrogation in the IL-15 KO mice was related to the absence of NK cells as well as an approximately 50% reduction of CD8⁺ T cells in the IL-15–deficient mice compared with the wild-type host (data not shown). These data, taken together, indicate that CD8⁺ T cells are essential in the antitumor activity of TP-DC + anti-CD137, whereas NK cells and CD4⁺ cells also play substantial roles.

Anti-CD137 Boosts the Proliferation of Antigen-reactive T Cells Induced by TP-DCs. Table 1 summarizes the cell yield obtained from VPLNs performed in four separate experiments. VPLNs were harvested 6 days after DC vaccination on day 0 followed by anti-CD137 administration on days 1 and 4. The administration of anti-CD137 alone did not result in an increase in the number of VPLN cells. The administration of UP-DCs or TP-DCs alone increased the cell yield of VPLNs compared non–DC-treated mice, but the values were not significantly different from each other. The combination of anti-CD137 and UP-DCs resulted in a VPLN cell yield that was not different from that seen with UP-DCs alone. However, the combination of anti-CD137 + TP-DCs resulted in a significantly higher cell yield in the VPLNs compared with TP-DCs alone or any other control groups. This suggested that the in vivo administration of anti-CD137 increased cell proliferation of antigen-reactive lymphoid cells that may have been sensitized by the TP-DC vaccine.

To explore this observation further, we used the OT-1 model that had a defined antigen-reactive T-cell population to OVA. As described in Materials and Methods, OT-1 CD8⁺ T cells were isolated, labeled with CFSE, and adoptively transferred intravenously into wild-type B6 mice on day 3. Subsequently, on day 0, the recipient mice were immunized with UP-DCs or DCs pulsed with B16-OVA tumor lysate. Groups of mice were given anti-CD137, and VPLN cells were harvested on day 6 for analysis of proliferation.

Table 1  Cell yield in vaccine-primed lymph nodes 6 days after inoculation

<table>
<thead>
<tr>
<th>No. of cells (10⁶ per LN)</th>
<th>Groups</th>
<th>Exp. 1</th>
<th>Exp. 2</th>
<th>Exp. 3</th>
<th>Exp. 4</th>
<th>Mean ± SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS + rat IgG</td>
<td>4.3</td>
<td>0.9</td>
<td>4.2</td>
<td>5.5</td>
<td>3.7</td>
<td>2.0</td>
</tr>
<tr>
<td>PBS + anti-CD137</td>
<td>3.0</td>
<td>0.2</td>
<td>7.4</td>
<td>2.6</td>
<td>3.3</td>
<td>3.3</td>
</tr>
<tr>
<td>UP-DC + rat IgG</td>
<td>23.0</td>
<td>10.0</td>
<td>22.6</td>
<td>20.0</td>
<td>18.9</td>
<td>6.1</td>
</tr>
<tr>
<td>UP-DC + anti-CD137</td>
<td>24.0</td>
<td>20.0</td>
<td>20.0</td>
<td>17.5</td>
<td>20.4</td>
<td>2.7</td>
</tr>
<tr>
<td>TP-DC + rat IgG</td>
<td>24.0</td>
<td>12.5</td>
<td>24.5</td>
<td>24.0</td>
<td>21.3</td>
<td>5.8</td>
</tr>
<tr>
<td>TP-DC + anti-CD137</td>
<td>30.0</td>
<td>30.0</td>
<td>47.5</td>
<td>37.0</td>
<td>36.1</td>
<td>8.3</td>
</tr>
</tbody>
</table>

Abbreviation: Exp., experiment.
Proliferation of the adoptively transferred OT-1 cells was assessed by measuring CFSE profiles of the VPLN cells using flow cytometry (Fig. 10). Mice given PBS, anti-CD137 alone, UP-DCs alone, or UP-DCs + anti-CD137 demonstrated minimal evidence of proliferation of OT-1 CD8+ T cells (~10%). There was a minor increase in the number of CFSE-positive cells after TP-DC (14%). However, the combination of anti-CD137 + TP-DC resulted in significant proliferation of CFSE-labeled OT-1 cells in the VPLNs (~34%). In addition, TP-DC + CD137 treatment increased the percentage of CD62Llow-expressing CFSE-labeled OT-1 cells (26%) compared with TP-DCs alone (11%), anti-CD137 alone (10%), and other control groups (~10%).

**Anti-CD137 Monoclonal Antibody Administration Polarizes T Cells Activated by TP-DCs Toward the Type 1 Phenotype via Natural Killer Cells.** As with the MCA 205 model, we found that anti-CD137 administration resulted in polarizing the immune response to tumor-associated antigen in the OT-1 model. As shown in Fig. 11A, the administration of anti-CD137 + TP-DC significantly enhanced IFN-γ secretion by VPLNs and spleen cells to OVA compared with TP-DC + rat IgG. By contrast, antigen-stimulated IL-4 release by both cell populations was significantly reduced to undetectable levels when anti-CD137 was given in addition to TP-DC vaccination (Fig. 11B).

We proceeded to examine the effect of depleting mAb to CD4 cells and NK cells in this experimental model. As described in Fig. 11A and B, depletion of host CD4+ T cells significantly reduced IFN-γ secretion induced by anti-CD137 + DC but did not alter IL-4 production. However, after depletion of host NK1.1+ cells, the enhanced IFN-γ secretion and the decreased IL-4 secretion due to the use of anti-CD137 + DC were abrogated to levels comparable with those induced by DC vaccination alone. These results indicate that the antitumor efficacy of anti-CD137 + TP-DC combined therapy was associated with T-cell polarization toward a type 1 pattern mediated by NK cells, in addition to CD4+ T-cell help.

**DISCUSSION**

We sought to determine whether anti-CD137 administration would be an effective adjuvant with DC-based vaccines and to evaluate what mechanisms were involved. An initial observation we made in our studies was that CD137 was up-regulated on a subset of VPLN T cells 3 days after TP-DC vaccination. This was not seen with the administration of UP-DCs, indicating that the pulsing with tumor lysate induced a functional difference in the DCs that mediated the activation of T cells in the VPLNs. Little information is available regarding the effects of tumor lysate uptake on DC function or biology. Grolleau et al. recently used microarray analysis to identify gene expression differences between UP-DCs and TP-DCs in the murine system and found a broad spectrum of immunomodulating genes that are altered by lysate pulsing. The mechanisms by which TP-DCs up-regulate CD137 on VPLN T cells remain to be elucidated.

We postulated that anti-CD137 administration may potentiate the antitumor reactivity of TP-DC therapy. Subsequent experiments demonstrated that administration of anti-CD137 enhanced the antitumor reactivity of TP-DC vaccines in both weakly (i.e., MCA 205) and poorly (i.e., B16-BL6) immunogenic tumor models. The combined therapy of anti-CD137 + TP-DC resulted in more effective therapy of advanced disease and improved survival and was effective in the postoperative setting in treating residual microscopic disease.

We found that anti-CD137 administration polarized the antitumor reactivity of T cells to tumor antigen toward a type 1 response (i.e., IFN-γ) and away from a type 2 response (i.e., IL-4). This was observed in the VPLNs and spleens of vaccinated mice. The results of this study extend our previous observations regarding the ability of anti-CD137 to polarize T-cell reactivity during *in vitro* culture (26). In that report, we examined the effects of anti-CD3, anti-CD28, and anti-CD137 on activating tumor-draining lymph node (TDLN) cells *in vitro*. Anti-CD3, with or without anti-CD28, up-regulated CD137.
expression on TDLN cells. The subsequent addition of anti-CD137 polarized the type 1 versus type 2 response of the TDLN cells and augmented their therapeutic efficacy in the adoptive immunotherapy of established tumor.

The in vivo antitumor reactivity of anti-CD137 + TP-DC vaccination was mediated by CD8⁺, CD4⁺, and NK cells. Among these lymphoid cells, CD8⁺ T cells manifested the most significant antitumor effect as compared with CD4⁺ and NK cells. Other reports examining anti-CD137 alone as an antitumor therapy have also found CD8⁺ cells to be critical (15, 27). The major role of CD8⁺ cells as effectors may relate to the relatively greater expression of CD137 on CD8⁺ cells compared with CD4⁺ cells after T-cell receptor engagement (28). The depletion of CD4⁺ or NK1.1⁺ lymphocyte subset, mice received intraperitoneal injection with GK 1.5 (400 μg) or PK136 (400 μg), respectively, on day –2.

We consistently found that TP-DC vaccines + anti-CD137 resulted in a greater cell yield from the VPLNs compared with UP-DC vaccine given with or without anti-CD137. To further investigate the mechanisms of this effect, we used the OT-1 transgenic model. We found that the increased number of cells in the LNs draining TP-DCs was due to the preferential accumulation of antigen-reactive OT-1 cells. These cells also demonstrated increased proliferation compared with OT-1 cells found in LNs draining UP-DCs. In addition, we found that the administration of anti-CD137 caused increased survival and proliferation of antigen-reactive cells (i.e., OT-1 CD8⁺ cells). Several groups have reported previously that anti-CD137 can promote survival of CD8⁺ T cells (30 –34). The induced proliferation of CD8⁺ cells by anti-CD137 is supported by some investigators (30 –33) but not by others (34). The majority of studies and our data would support the former.

The polarization effect of anti-CD137 was also observed in the OT-1 model. The depletion of NK cells, but not CD4⁺ cells, reversed the polarization effect of the cytokine response of both VPLNs and splenocytes. These findings demonstrate a novel interaction between anti-CD137-activated NK cells and T cells. The cross-talk between NK cells and CD8⁺ cells that promotes expansion and increased lytic activity as reported by Wilcox et al. (29) be related to the
cytokine milieu seen in our studies; namely, the down-regulation of type 2 cytokines.

In summary, there are several salutary effects of anti-CD137 when administered in conjunction with tumor vaccines. These include polarization of tumor-reactive T-cell responses toward a type 1 profile, increased survival and proliferation of activated T cells, and activation of NK cells that interact with the adaptive immune system in the polarization process. This provides a useful tool to break immunologic “ignorance” to poorly immunogenic tumors, making the combined therapy using this antibody and TP-DC vaccine more effective.

ACKNOWLEDGMENTS

We thank Kerry Odneal for excellent secretarial assistance in putting together the manuscript.

REFERENCES

5. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 2002;169:5227–35.
Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines

Fumito Ito, Qiao Li, Andrew B. Shreiner, et al.

Cancer Res 2004;64:8411-8419.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/22/8411

Cited articles
This article cites 31 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/22/8411.full.html#ref-list-1

Citing articles
This article has been cited by 17 HighWire-hosted articles. Access the articles at:
/content/64/22/8411.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.